Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Meredith C, Foster"'
Autor:
M. Judith Peterschmitt, Selena Freisens, Lisa H. Underhill, Meredith C. Foster, Grace Lewis, Sebastiaan J. M. Gaemers
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 14, Iss 1, Pp 1-13 (2019)
Abstract Background Eliglustat is a first-line oral treatment for adults with Gaucher disease type 1 who have an extensive, intermediate or poor CYP2D6 metabolizer phenotype (> 90% of patients). Whereas enzyme replacement therapy for Gaucher disease
Externí odkaz:
https://doaj.org/article/1a7c6cc74994420bad517ed4fc512db9
Autor:
Dominik Steubl, Li Fan, Wieneke M. Michels, Lesley A. Inker, Hocine Tighiouart, Friedo W. Dekker, Raymond T. Krediet, Andrew L. Simon, Meredith C. Foster, Amy B. Karger, John H. Eckfeldt, Hongyan Li, Jiamin Tang, Yongcheng He, Minyan Xie, Fei Xiong, Hongbo Li, Hao Zhang, Jing Hu, Yunhua Liao, Xudong Ye, Tariq Shafi, Wei Chen, Xueqing Yu, Andrew S. Levey
Publikováno v:
Kidney Medicine, Vol 1, Iss 3, Pp 104-114 (2019)
Rationale & Objective: Measurement of residual kidney function is recommended for the adjustment of the dialysis prescription, but timed urine collections are difficult and prone to errors. Equations to calculate residual kidney function from serum c
Externí odkaz:
https://doaj.org/article/43df496664724b0ca364d4479d0a3620
Autor:
Tina, Duong, Priya S, Kishnani, Kristina, An Haack, Meredith C, Foster, James B, Gibson, Catherine, Wilson, Si Houn, Hahn, Richard, Hillman, David, Kronn, Nancy D, Leslie, Loren D M, Peña, Susan E, Sparks, David W, Stockton, Pranoot, Tanpaiboon, John W, Day
Publikováno v:
Journal of Neuromuscular Diseases. 9:713-730
Background: ADVANCE (NCT01526785) presented an opportunity to obtain a more nuanced understanding of motor function changes in treatment-experienced children with Pompe disease receiving 4000L-production-scale alglucosidase alfa for 52 weeks. Objecti
Autor:
Amy D. Shapiro, Roshni Daniel Kulkarni, Margaret V Ragni, Herve Chambost, Johnny N Mahlangu, Johannes Oldenburg, Beatrice Nolan, Margareth C Ozelo, Meredith C Foster, Annemieke Willemze, Chris Barnowski, Nisha Jain, Bent Winding, Jennifer Dumont, Stefan Lethagen, Chris Barnes, K John Pasi
Publikováno v:
Blood Advances.
Long-term efficacy and safety of the extended half-life recombinant FIX Fc fusion protein (rFIXFc) has been established in previously treated patients with severe hemophilia B in 2 Phase 3 trials (B-LONG [NCT01027364] and Kids B-LONG [NCT01440946]) a
Autor:
Sebastiaan J.M. Gaemers, Pramod K. Mistry, Joel Charrow, Theodore Marinakis, Meredith C. Foster, Timothy M. Cox, M. Judith Peterschmitt, Elena Lukina
Debilitating bone complications are common among patients with Gaucher disease type 1 (GD1). We analyzed changes in bone parameters among 393 GD1 patients treated with oral eliglustat for 4–8 years in 4 Sanofi Genzyme-sponsored clinical trials (Pha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20c5446ad43678bf72d667b32ead022f
Autor:
Thomas G. Martin, Marcelo Capra, Mohamad Mohty, Kenshi Suzuki, Hang Quach, Michele Cavo, Philippe Moreau, Meletios Dimopoulos, Kwee Yong, Christina Tekle, Meredith C. Foster, Yvonne Barnes, Marie-Laure Risse, Joseph Mikhael
Publikováno v:
Transplantation and cellular therapy.
In the era of highly active novel agents for multiple myeloma (MM), the role, ideal timing, and impact of transplantation on further therapy after relapse remains a matter of debate. The impact of prior transplantation on treatment benefit from monoc
Autor:
Pramod K. Mistry, Evgueniy Hadjiev, Sebastiaan J.M. Gaemers, Suma P. Shankar, Marwan Ghosn, Sarit Assouline, Andres Ortega, Heather Lau, Seymour Packman, Sumita Danda, Elena Lukina, M. Judith Peterschmitt, Hagit Baris Feldman, Milan Petakov, Hadhami Ben Turkia, Meredith C. Foster, Atul Mehta, Manisha Balwani
Publikováno v:
American Journal of Hematology
Eliglustat, an oral substrate reduction therapy, is approved for eligible adults with Gaucher disease type 1. In the Phase 3 ENGAGE trial of previously untreated adults with Gaucher disease type 1, eliglustat‐treated patients had statistically sign
Publikováno v:
Molecular Genetics and Metabolism. 138:107527
Publikováno v:
SSRN Electronic Journal.
Autor:
Timothy M. Cox, Joel Charrow, Elena Lukina, Pramod K. Mistry, Meredith C. Foster, M. Judith Peterschmitt
Publikováno v:
Genetics in Medicine. 25:100329
Most patients with Gaucher disease have progressive and often disabling skeletal manifestations. We examined the long-term effect of eliglustat treatment on bone outcomes in clinical trials in adults with Gaucher disease type 1.Data from 4 completed